News from juventas therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 16, 2015, 08:05 ET Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy

Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to...


May 12, 2015, 09:10 ET Juventas Therapeutics Adds $13.5 Million In New Financing And Expands Board Of Directors

Juventas Therapeutics, Inc., a clinical-stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular...


Aug 12, 2014, 09:05 ET Juventas Therapeutics completes enrollment of Phase I/II RETRO-HF trial and demonstrates safety for retrograde infusion of JVS-100 in patients with heart failure

Juventas Therapeutics, Inc., a private clinical-stage company developing a drug-based approach to regenerative medicine today announced that it...


May 06, 2014, 09:00 ET Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at European Society of Cardiology Heart Failure Congress

Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking oral...


Feb 04, 2014, 09:00 ET Juventas Therapeutics initiates Phase II RETRO-HF clinical trial enrollment for patients with heart failure

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for the treatment of cardiovascular...


Dec 09, 2013, 09:35 ET Juventas Therapeutics initiates first clinical trial for retrograde infusion of a gene therapy to patients with heart failure

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease,...